IDH1 and astrocytoma (excluding glioblastoma): In contrast, WHO grading remained significant for IDH-mut astrocytoma (Fig. 1c), contradicting several previous reports (Reuss et al. 2015b; Cimino and Holland 2019; Aoki et al. 2018; Olar et al. 2015).